Silver Nanoparticles — Quality and Particle Size

"Colloidal silver" is a poorly-defined consumer category covering products with 100× differences in particle size, surface chemistry, total silver concentration, and ionic-vs-particulate ratio. A 10 ppm "true colloidal" product with 5-15 nm nanoparticles and a 30 ppm "ionic silver" product are functionally different therapeutics that happen to share a name. The same is true for "silver protein" products that suspend much larger particles in a gelatin matrix, "silver chloride" products formed when silver reacts with chloride in saline, and homemade preparations whose properties depend on the electrolysis voltage, current, water purity, and reaction time. This page explains the relevant distinctions, how particle size affects both activity and toxicity, why independent ICP-MS measurement matters, and how to read product specifications and third-party assays without being misled by marketing language.

Table of Contents

1. "Colloidal Silver" as a Catch-All Category
2. Why Particle Size Matters — Activity and Toxicity
3. Ionic Silver vs Particulate Silver
4. Silver Protein (Mild and Strong)
5. Silver Chloride and Reaction Products
6. Homemade Colloidal Silver — Why Variability Is Extreme
7. Concentration Units: ppm, mg/L, and What They Actually Mean
8. Characterization Techniques (ICP-MS, DLS, TEM)
9. Reading Product Labels Without Being Misled
10. Third-Party Testing and Independent Assays
11. Key Research Papers
12. Connections

"Colloidal Silver" as a Catch-All Category

The phrase "colloidal silver" is used loosely in the consumer market to describe several distinct categories of silver-containing solution that share a common visual appearance (yellowish-amber to brown clear or slightly cloudy liquid) but differ enormously in their physical chemistry and biological behavior. The major categories are:

• True colloidal silver — suspension of metallic silver nanoparticles (typically 1-100 nm in diameter) in water, with the nanoparticles kept in suspension by their own surface charge and/or a stabilizing agent (citrate, polyvinylpyrrolidone, gelatin). The characteristic yellow-to-brown color is due to surface plasmon resonance of the silver nanoparticles, not to dissolved silver salts.
• Ionic silver solutions — aqueous solutions of dissolved silver salts (silver nitrate, silver oxide, etc.) with silver predominantly present as Ag+ ions rather than nanoparticles. Generally colorless or pale.
• Silver protein products — silver bound to gelatin or other protein matrix; particle size is typically larger (50-1000 nm); higher total silver loading per volume but lower bioavailable silver ion.
• Silver chloride suspensions — AgCl is essentially insoluble and biologically inactive; many "colloidal silver" products gradually accumulate silver chloride content if exposed to chloride-containing water or stored long-term.
• Mixed products — most commercial "colloidal silver" is actually a mixture of nanoparticulate silver, ionic silver, and various reaction byproducts. The exact ratios are often unspecified and may vary batch to batch.

These categories have substantially different antimicrobial potency per mg of silver, different rates of GI absorption, different argyria risk per mg ingested, and different stability over time. A consumer choosing a "colloidal silver" product without knowing which category it falls into has limited basis for predicting how it will actually behave.

Back to Table of Contents

Why Particle Size Matters — Activity and Toxicity

Silver nanoparticle particle size is the single most important physical-chemistry variable determining biological activity. The relationship is dominated by surface area: a nanoparticle 5 nm in diameter has approximately 4× the surface area per unit mass of a 20 nm nanoparticle, and approximately 40× the surface area per unit mass of a 200 nm particle. Since silver ion release depends on surface oxidation, smaller particles release Ag+ much faster.

The empirical relationship between size and antimicrobial activity has been well-characterized:

• 1-10 nm particles — maximum antimicrobial activity per mass of silver. The Morones 2005 study found that only particles smaller than 10 nm directly interacted with bacterial membranes, while larger particles relied entirely on slow Ag+ release.
• 10-50 nm particles — substantial activity through Ag+ release; size of most commercial "nanocrystalline silver" wound dressings (Acticoat uses approximately 15 nm particles).
• 50-100 nm particles — reduced activity per mass; still functional but requires longer exposure for equivalent kill.
• Larger than 100 nm — essentially inert except for the slow Ag+ released at the surface; many "colloidal silver" products with poor manufacturing fall in this range despite "colloidal" marketing.

Toxicity scales somewhat differently with particle size. Smaller particles produce higher peak Ag+ concentration faster, which is good for antimicrobial effect at the wound site but can produce higher local cytotoxicity to host cells. Very small particles (less than 5 nm) can also enter mammalian cells more easily and produce intracellular oxidative damage. The "sweet spot" for topical wound applications is typically the 10-20 nm range used in commercial dressings — small enough for effective antimicrobial activity, large enough to avoid extreme cytotoxicity and to provide sustained Ag+ release rather than a burst.

For internal use, the picture is more concerning. Smaller particles have higher GI absorption rates (some animal studies suggest 10-20% absorption of sub-10-nm particles vs less than 1% for larger particles). This means a sub-10-nm colloidal silver product produces substantially higher systemic silver exposure per oral dose than a larger-particle product at the same nominal ppm concentration, with correspondingly higher argyria risk.

Back to Table of Contents

Ionic Silver vs Particulate Silver

The distinction between ionic silver and particulate (nanoparticle) silver is technically important and frequently misrepresented in product marketing.

Ionic silver: Silver dissolved as free Ag+ ions in solution. Common sources include silver nitrate solutions and the partial dissolution of silver nanoparticles. Ionic silver is immediately bioavailable as Ag+ but is also chemically reactive — it precipitates with chloride to form silver chloride (insoluble), with phosphate to form silver phosphate, and binds avidly to proteins. In the stomach, ionic silver immediately encounters hydrochloric acid and chloride, converting most of it to silver chloride which is then largely excreted unabsorbed in feces. This is paradoxically protective against argyria from oral ionic silver, but also limits any therapeutic effect.

Particulate (nanoparticle) silver: Silver as metallic nanoparticles (Ag0) that release Ag+ slowly at their surface. The nanoparticles themselves can survive stomach acid (unlike ionic silver), pass through the gut wall more efficiently than ionic silver, and continue releasing Ag+ in tissue. This makes nanoparticulate silver more bioavailable and more potent per mg ingested — which is good for antimicrobial effect but also means higher systemic absorption and higher cumulative argyria risk.

Commercial products vary widely in their ionic-vs-particulate ratio. Some "ionic silver" products are essentially silver nitrate solutions in disguise. Some "true colloidal silver" products are 90%+ nanoparticulate with minimal ionic content. Many products are mixtures with no specified ratio.

This matters for both efficacy and safety claims. Marketing language like "more bioavailable" or "small particle size for maximum absorption" implies higher efficacy but also implies higher systemic loading and faster argyria accumulation. There is no free lunch — the same property that makes a colloidal silver product more "effective" makes it more dangerous to use chronically.

Back to Table of Contents

Silver Protein (Mild and Strong)

Silver protein products are an older category that pre-dates modern nanoparticle synthesis. They consist of silver complexed with a protein matrix (historically gelatin or casein) that suspends much larger silver particles than would otherwise stay in solution. Two main subcategories:

• Mild Silver Protein (Argyrol) — approximately 10-25% silver by weight, used historically as a topical antiseptic for mucous membranes (eyes, throat, vagina). Argyrol was developed by Albert Barnes in 1902 and was a major commercial product until the introduction of antibiotics. Some mild silver protein products are still marketed for nasal and throat use.
• Strong Silver Protein — higher silver content (up to 30-40%), used historically for severe topical infections; largely replaced by modern antibiotics.

Silver protein products have advantages and disadvantages:

• Higher silver loading per volume than typical colloidal silver (good for topical antimicrobial effect)
• Larger particle size means less GI absorption when ingested (lower argyria risk per mg)
• But the larger particles also mean less Ag+ release per unit mass (lower antimicrobial activity per mg)
• Protein matrix can support bacterial growth if not properly preserved (though silver in the product usually prevents this)
• Some silver protein products have produced more argyria cases historically than would be expected from particle size alone, possibly because the protein-stabilized silver is taken up by tissue macrophages more efficiently

The FDA 1999 final rule specifically named silver protein products as among the OTC silver products that may not be marketed with disease claims.

Back to Table of Contents

Silver Chloride and Reaction Products

Silver chloride (AgCl) is an essentially insoluble silver salt that forms whenever ionic silver encounters chloride ions. This matters for colloidal silver products in several ways:

• Manufacturing — if tap water (which contains chloride from chlorination) is used in colloidal silver production, much of the silver ends up as AgCl rather than as free Ag+ or nanoparticles. Distilled water is essential.
• Storage — many colloidal silver products develop AgCl content over time as residual chloride reacts with the silver. Products that turn cloudy in storage often have AgCl formation.
• Stomach exposure — in the stomach, ionic silver immediately reacts with hydrochloric acid to form AgCl, which is then largely excreted unabsorbed. This is the main reason oral ionic silver has limited systemic bioavailability compared to nanoparticulate silver, which survives gastric acid largely intact.
• Biological inactivity — AgCl itself is essentially inactive as an antimicrobial because it does not release Ag+ in significant concentration at physiologic pH.

A colloidal silver product that has developed substantial AgCl content has lower antimicrobial activity than its nominal silver concentration would suggest, but it also has lower bioavailability and lower argyria risk per mg of total silver. The net therapeutic effect is generally lower without commensurate safety advantage.

Back to Table of Contents

Homemade Colloidal Silver — Why Variability Is Extreme

Many colloidal silver users make their own product using DC electrolysis — a low-voltage power source connected to two silver electrodes immersed in distilled water. Silver dissolves from the anode as Ag+ ions, some of which reduce back to nanoparticulate silver as the process continues. The simplicity of the setup masks the chemistry, which is actually quite sensitive to operating parameters:

• Voltage and current — higher current produces higher silver release rate but also produces larger particles and more agglomerated products. Most reputable home-production tutorials specify low current (less than 1 mA) for fine particle production.
• Electrode purity — sterling silver (92.5%) contains 7.5% copper, which co-electrodes and produces silver-copper colloidal mixtures rather than pure silver. .999 fine silver wire is essential.
• Water purity — distilled water is required; tap water produces silver chloride rather than colloidal silver.
• Reaction time — longer time produces higher silver concentration but also more particle agglomeration; "endpoint" is poorly defined.
• Temperature — affects silver solubility, particle nucleation kinetics, and final ionic-vs-particulate ratio.
• Container — glass is required; metals leach into the product.
• Stirring vs static — affects particle size distribution.
• Sealing and storage — affects oxidation and AgCl formation post-production.

The result is that homemade colloidal silver from two different operators (or even two different runs by the same operator) can vary by 10× or more in actual silver concentration, particle size distribution, and ionic-vs-particulate ratio. Most home-production users have no way to assay their finished product and rely on conductivity meters or visual color as proxies — both of which are poor proxies for actual silver content.

This extreme variability is the primary reason the FDA and CDC warn against homemade silver products specifically. Even if commercial colloidal silver use carries documented argyria risk, homemade products have additional risk from unpredictable silver concentration, contamination with copper from sterling silver, AgCl formation from impure water, and unpredictable bioavailability.

Back to Table of Contents

Concentration Units: ppm, mg/L, and What They Actually Mean

Silver product labels typically express concentration in parts per million (ppm), which for dilute aqueous solutions is essentially the same as mg/L. So a "30 ppm" colloidal silver product contains approximately 30 mg of total silver per liter, or 30 micrograms per milliliter.

What the ppm number does NOT tell you:

• The ionic-vs-particulate ratio (a 30 ppm ionic silver product behaves very differently from a 30 ppm nanoparticle product)
• The particle size distribution (a 30 ppm product with 5 nm particles is very different from a 30 ppm product with 100 nm particles)
• The actual silver concentration as opposed to nominal/claimed concentration (independent assays of commercial products have found wide discrepancies)
• The silver chloride content (which is biologically inert)
• The age of the product (silver content typically degrades over time)

Some products use other concentration descriptions:

• "Strong" or "concentrate" formulations — typically 100-1000 ppm
• "Hydrosol" — just a fancy word for aqueous colloidal solution; no specific concentration meaning
• "Silver hydrosol" — same as above; marketing language
• "Bio-Active" or "Active" silver — marketing language with no standardized meaning

For dose math: 1 teaspoon (5 mL) of 10 ppm contains 50 mcg silver; 1 teaspoon of 30 ppm contains 150 mcg silver; 1 teaspoon of 500 ppm contains 2,500 mcg silver. Daily doses approaching or exceeding the EPA chronic oral reference dose (350 mcg/day for a 70 kg adult) are easy to reach with common consumer products.

Back to Table of Contents

Characterization Techniques (ICP-MS, DLS, TEM)

Proper characterization of a silver nanoparticle product requires multiple complementary analytical techniques because no single method captures all the relevant physical chemistry. The most important techniques:

• ICP-MS (Inductively Coupled Plasma Mass Spectrometry) — the gold standard for measuring total silver content. Accurate to parts-per-billion; widely available in commercial testing labs. Reports total silver mass per volume but does not distinguish ionic from particulate.
• Single-particle ICP-MS — advanced variant that can resolve individual nanoparticles and measure particle size distribution alongside ionic silver concentration. Available in some specialized labs.
• DLS (Dynamic Light Scattering) — measures hydrodynamic particle size distribution in solution. Works well for monodisperse samples with relatively narrow size distributions; less informative for polydisperse mixtures.
• TEM (Transmission Electron Microscopy) — direct imaging of individual nanoparticles; gives high-resolution size and shape information. Sample preparation can alter the particle state, and only a small number of particles are typically imaged.
• UV-Vis spectroscopy — the silver surface plasmon resonance produces a characteristic absorption peak around 400-420 nm for spherical particles in the 10-50 nm range. Peak position shifts with particle size; peak width broadens with size distribution; the technique can give quick qualitative information about particle state.
• Zeta potential — measures particle surface charge; affects stability and bacterial-membrane interaction.

Reputable manufacturers will typically publish ICP-MS verification of nominal silver concentration on each batch; some also publish TEM or DLS data showing particle size distribution. Lack of any independent characterization data is a meaningful red flag.

Back to Table of Contents

Reading Product Labels Without Being Misled

Useful information that should appear on a quality colloidal silver product label:

• Specific silver concentration in ppm or mg/L (not just "concentrated" or "strong")
• Statement of particle size or size range
• Statement of ionic vs particulate content (e.g., "85% nanoparticle, 15% ionic")
• Manufacturing date and expiration date
• Storage instructions (typically dark glass, away from light, room temperature)
• Reference to independent third-party verification or COA (certificate of analysis)

Marketing language to view skeptically:

• "Most bioavailable" — usually means smaller particles, which means higher systemic loading and higher argyria risk
• "Purest" — marketing language with no specific meaning
• "Patented technology" — patents are easy to obtain; do not guarantee product quality
• "Used by [physician name]" — testimonial marketing; does not constitute clinical evidence
• "FDA approved" — no internal colloidal silver product has FDA approval; this claim is false on its face
• "Clinical strength" — meaningless marketing term
• Specific disease claims (treats X, cures Y) — illegal under DSHEA and FDA regulations

Back to Table of Contents

Third-Party Testing and Independent Assays

Several independent testing organizations have analyzed commercial colloidal silver products over the years and consistently found significant discrepancies between label claims and actual product content:

• ConsumerLab.com has conducted multiple rounds of independent assays of colloidal silver products. Results have included products containing significantly less silver than labeled, products with high silver chloride content, products with much larger particles than "nanoparticle" labeling implied, and products with batch-to-batch variability of 50% or more.
• Academic studies (Tulve 2015 and others) have surveyed commercial colloidal silver products using ICP-MS and TEM, similarly finding wide variability and frequent discrepancies between marketing claims and physical reality.
• FTC enforcement — multiple consent decrees have been signed by colloidal silver marketers for both false medical claims and false product characterization claims.

The general pattern: the colloidal silver consumer market includes both reputable manufacturers with consistent product characterization and significant manufacturers whose product specifications are aspirational rather than literal. Without independent third-party verification, consumers have no reliable way to distinguish the two.

For patients who, despite the safety profile, still wish to use colloidal silver, several practical recommendations follow: choose commercial products with published third-party COA data; limit dose to well below the EPA chronic oral RfD; use short courses rather than continuous chronic use; do not exceed manufacturer-recommended dosing; monitor for any skin discoloration (early argyria may be subtle); avoid concomitant use with quinolones, tetracyclines, levothyroxine, or penicillamine; avoid use entirely during pregnancy, lactation, in children, and in patients with chronic kidney disease.

Back to Table of Contents

Key Research Papers

1. Morones JR et al. (2005). The bactericidal effect of silver nanoparticles. Nanotechnology. — PMID 20818017
2. Chernousova S, Epple M (2013). Silver as antibacterial agent: ion, nanoparticle, and metal. Angewandte Chemie. — PMID 23280986
3. Tulve NS et al. (2015). Characterization of silver nanoparticles in selected consumer products and its relevance for predicting children's potential exposures. Int J Hyg Environ Health. — PMID 25435060
4. Liu J, Hurt RH (2010). Ion release kinetics and particle persistence in aqueous nano-silver colloids. Environ Sci Technol. — PMID 20121184
5. Levard C et al. (2012). Environmental transformations of silver nanoparticles: impact on stability and toxicity. Environ Sci Technol. — PMID 22655746
6. Lok CN et al. (2007). Silver nanoparticles: partial oxidation and antibacterial activities. J Biol Inorg Chem. — PMID 17225061
7. Pal S et al. (2007). Does the antibacterial activity of silver nanoparticles depend on the shape of the nanoparticle? A study of the Gram-negative bacterium Escherichia coli. Appl Environ Microbiol. — PMID 17277223
8. Loza K et al. (2014). The dissolution and biological effects of silver nanoparticles in biological media. J Mater Chem B. — PubMed
9. Kittler S et al. (2010). Toxicity of silver nanoparticles increases during storage because of slow dissolution under release of silver ions. Chem Mater. — PubMed
10. Mitrano DM et al. (2014). Detecting nanoparticulate silver using single-particle inductively coupled plasma-mass spectrometry. Environ Toxicol Chem. — PMID 22517505
11. Carlson C et al. (2008). Unique cellular interaction of silver nanoparticles: size-dependent generation of reactive oxygen species. J Phys Chem B. — PMID 18800818
12. Wijnhoven SWP et al. (2009). Nano-silver — a review of available data and knowledge gaps in human and environmental risk assessment. Nanotoxicology. — PubMed

PubMed Topic Searches

• PubMed: Silver nanoparticle size and activity
• PubMed: Ionic vs nanoparticle silver
• PubMed: ICP-MS silver product characterization
• PubMed: Silver nanoparticle dissolution kinetics
• PubMed: Silver protein history

Back to Table of Contents

Connections

• Silver Nanoparticles (Hub)
• Silver Nanoparticles Benefits Hub
• Antimicrobial Mechanism
• Argyria Risk and Cautions
• Topical vs Internal Use
• Silver and Meningitis
• Silver and Epstein-Barr Virus
• All Remedies
• Infectious Disease
• Dermatology
• Toxins Index
• Heavy Metals
• Copper
• Lab Tests
• Diseases Index

Back to Table of Contents